Scientists have discovered a new antibiotic called evybactin that is able to selectively target Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB) lung infections. As described in Nature Chemical Biology on Aug. 22, 2022. the work is still at an early stage and requires further validation. But, if successful in clinical trials, evybactin could form part of a new group of specific antibiotics designed to target TB. Read More

Anakuria Therapeutics Inc. has identified rapamycin derivatives acting as mTOR complex 1 (mTORC1) inhibitors reported to be useful for the treatment of diabetic nephropathy, chronic obstructive pulmonary disease, epilepsy, fragile X syndrome, urinary tract infection, heart failure, glaucoma and autosomal dominant polycystic kidney, among others. Read More

The FDA has cleared Inhibikase Therapeutics Inc.'s IND application for IkT-001Pro for the treatment of chronic myelogenous leukemia (CML). IkT-001Pro is a prodrug formulation of imatinib mesylate and has been developed to improve the safety of the first FDA-approved Abelson (Abl) kinase inhibitor, Gleevec (imatinib). Read More

Ideaya Biosciences Inc. reported the achievement of the first preclinical development milestone under its ongoing collaboration with GSK plc for a polymerase (Pol) theta-helicase development candidate. Read More

Data on the development of novel noncationic macrocyclic peptides for inhibiting GTPase KRAS signaling for the potential treatment of cancer were presented by investigators from Merck & Co. Inc. Read More

Southern Marine Science and Engineering Guangdong Laboratory and Guangdong Medical University have disclosed peptides acting as angiotensin-converting enzyme (ACE) inhibitors reported to be useful for the treatment of hypertension. Read More

GSK plc presented data on the discovery of a selective and potent lead series for G protein-coupled receptor kinase 2 (GRK2) inhibition for the potential treatment of heart failure. Heart failure remains a leading cause of morbidity and mortality worldwide. Read More

Preserving beta-cell mass and expansion is a key point in diabetes. Prolonged hyperglycemia may lead to glucose toxicity, which impairs insulin production and secretion, promoting a cycle with increasing glucose concentrations that promote a decline of beta-cell function and eventually their death. Read More

Sirnaomics Ltd. reported progress with its Galahead RNAi delivery platform for developing novel therapeutic products focused on complement-related diseases. Read More

Academy of Military Medical Sciences (AMMS) has divulged 3C-like proteinase (viral) and 3C protease (viral) inhibitors reported to be useful for the treatment of viral infections. Read More

Researchers from Novartis AG recently presented data for a novel NMDA receptor 2B (NR2B) negative allosteric modulator (NAM), onfasprodil (MIJ-821). Read More